One year after the WHO alert for COVID-19: what is next? / Um ano após o alerta da OMS para COVID-19: o que vem a seguir?

Authors

  • Thyago José Arruda Pacheco Brazilian Journals Publicações de Periódicos, São José dos Pinhais, Paraná
  • Danielle Galdino de Souza
  • Karla Natyara Novais Borges
  • Juliana de Oliveira Pires
  • Angela Santos Silva Fabbrin
  • Pedro Henrique Macedo dos Santos
  • Maria Blandina Santos Borges

DOI:

https://doi.org/10.34117/bjdv7n3-626

Keywords:

COVID-19, Coronavirus, Pandemic, Sars-CoV-2, WHO.

Abstract

In December 2019, an outbreak of atypical pneumonia was discovered, later revealed to be due to a new virus identified as SARS-CoV-2, responsible for causing the coronavirus disease (COVID-19). The purpose is brings the main changes and discoveries, after a year that PHEIC was declared. We argue that after one year since PHEIC was declared, a lot has changed since then, in this sense, carried out a bibliographic review. We conducted a survey of articles published in the PUBMED and Google Scholar databases, from January 2020 to January 2021, which released data from studies related to transmission, treatment, vaccines, new variants for COVID-19. After the novel virus spread to other countries and caused hundreds of deaths, the World Health Organization issued its alarm on January 30, 2020, known as PHEIC. After a year that the alarm was given a lot has changed. The first major change was the beginning of a COVID-19 pandemic on March 11, 2020. Many discoveries were made, from a better understanding of transmission, treatment, vaccines and challenges with new strains that arose after selective pressure.

 

 

References

BEIGEL, J.H. et al. Remdesivir for the treatment of Covid-19. N Engl J Med, England, v. 383, n. 19, p. 1813–26, 2020. Acess in: 30 jan. 2021

CALLAWAY, E. Fast-spreading COVID variant can elude immune responses. Nature, England, 2021a. Acess in: 30 jan. 2021

CALLAWAY, E.; MALLAPATY, S. Novavax offers first evidence that COVID vaccines protect people against variants. Nature [Internet], England, 2021b. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33510489. Acess in: 30 jan. 2021

CASCELLA, M. et al. Features, evaluation and treatment coronavirus (COVID-19). Statpearls [internet], 2020. Acess in: 30 jan. 2021

DUAN, K. et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci., v. 117, n. 17, p. 9490–6, 2020. Acess in: 30 jan. 2021

FELSENSTEIN, S. et al. COVID-19: Immunology and treatment options. Clin Immunol, v. 108448, 2020. Acess in: 30 jan. 2021

GAUTRET, P. et al. Natural history of COVID-19 and therapeutic options. Expert Rev Clin Immunol, England, p. 1–24, 2020. Acess in: 30 jan. 2021

HARTLEY, D.M.; PERENCEVICH, E.N. Public health interventions for COVID-19: emerging evidence and implications for an evolving public health crisis. Jama, United States, v. 323, n. 19, p. 1908–9, 2020. Acess in: 30 jan. 2021

HILL, A. et al. Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection. Research Square, 2021. DOI: 10.21203/rs.3.rs-148845/v1. Acess in: 30 jan. 2021

ITA, K. Coronavirus Disease (COVID-19): Current Status and Prospects for Drug and Vaccine Development. Arch Med Res, Mexico, v. 52, n. 1, p. 15, 2021. Acess in: 30 jan. 2021

JAN, H. et al. COVID-19: review of epidemiology and potential treatments against 2019 novel coronavirus. Discoveries, v. 8, n. 2, 2020. Acess in: 30 jan. 2021

KEMP, SA. et al. Neutralising antibodies drive Spike mediated SARS-CoV-2 evasion (medRxiv). bioRxiv, 2020; Acess in: 30 jan. 2021

KUPFERSCHMIDT, K. Mutant coronavirus in the United Kingdom sets off alarms, but its importance remains unclear. Sci December, v. 20, 2020. Acess in: 30 jan. 2021

KUPFERSCHMIDT, K. Vaccinemakers ponder how to adapt to virus variants. American Association for the Advancement of Science, 2021. Acess in: 30 jan. 2021

LEWIS, D. COVID-19 rarely spreads through surfaces. So why are we still deep cleaning? Nature [Internet], England, v. 590, n. 7844, p. 26–8, 2021. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33514939. Acess in: 30 jan. 2021

LI, Q. et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med, England, v. 382, n. 13, p. 1199–207, 2020. Acess in: 30 jan. 2021

MAXMEN, A. Why did the world’s pandemic warning system fail when COVID hit? Nature [Internet], England, v. 589, n. 7843, p. 499—500, 2021. Available from: https://doi.org/10.1038/d41586-021-00162-4. Acess in: 30 jan. 2021

MOORE, J.P.; OFFIT, P.A. SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants. JAMA, 2021. Acess in: 30 jan. 2021

PACHECO, T.J.A. et al. Coronavirus disease 2019 (COVID-19): Updated evidence of comparative overview, diagnosis and treatments. Rev Cereus, Brazil, v. 12, n. 3, p. 228–43, 2020a. Acess in: 30 jan. 2021

PACHECO, T.J.A. et al. Nano COVID-19 Vaccines: the firsts RNA lipid nanoparticle vaccines being approved from history-Review. Res Soc Dev, Brazil, v. 9, n. 12, p. e20191211123--e20191211123, 2020b. Acess in: 30 jan. 2021

POLLOCK, A.M.; LANCASTER, J. Asymptomatic transmission of covid-19. BMJ [Internet], England, v. 371, 2020. Available from: https://www.bmj.com/content/371/bmj.m4851. Acess in: 30 jan. 2021

RAJENDRAN, K. et al. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. J Med Virol, v. 92, n. 9, p. 1475–83, 2020. Acess in: 30 jan. 2021

RUEBUSH, E. et al. COVID-19 case investigation and contact tracing: early lessons learned and future opportunities. J Public Heal Manag Pract, United States, v. 27, n. 1, p. S87-S97, 2021. Acess in: 30 jan. 2021

SABINO, E.C. et al. Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. Lancet, 2021. Acess in: 30 jan. 2021

SHI, P-Y. et al. Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera. 2021. Acess in: 30 jan. 2021

TEGALLY, H. et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv, 2020. Acess in: 30 jan. 2021

VAN DOREMALEN, N. et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med [Internet], England, v. 382, n. 16, p. 1564–7, 2020. Available from: https://doi.org/10.1056/NEJMc2004973. Acess in: 30 jan. 2021

VOLOCH, C.M. et al. Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil. medRxiv [Internet], 2020; Available from: https://www.medrxiv.org/content/early/2020/12/26/2020.12.23.20248598. Acess in: 30 jan. 2021

XIE, C. et al. The evidence of indirect transmission of SARS-CoV-2 reported in Guangzhou, China. BMC Public Health, England, v. 20, n. 1, p. 1–9, 2020. Acess in: 30 jan. 2021

WANG, P. et al. Increased Resistance of SARS-CoV-2 Variants B. 1.351 and B. 1.1. 7 to Antibody Neutralization. bioRxiv, 2021. Acess in: 30 jan. 2021

WHO. Draft landscape and tracker of COVID-19 candidate vaccines [Internet]. [cited 2021 Feb 4]. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Acess in: 30 jan. 2021

Downloads

Published

2021-03-24

How to Cite

Pacheco, T. J. A., de Souza, D. G., Borges, K. N. N., Pires, J. de O., Fabbrin, A. S. S., dos Santos, P. H. M., & Borges, M. B. S. (2021). One year after the WHO alert for COVID-19: what is next? / Um ano após o alerta da OMS para COVID-19: o que vem a seguir?. Brazilian Journal of Development, 7(3), 29968–29978. https://doi.org/10.34117/bjdv7n3-626

Issue

Section

Original Papers